[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1414401A1 - Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques - Google Patents

Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques

Info

Publication number
EP1414401A1
EP1414401A1 EP02760258A EP02760258A EP1414401A1 EP 1414401 A1 EP1414401 A1 EP 1414401A1 EP 02760258 A EP02760258 A EP 02760258A EP 02760258 A EP02760258 A EP 02760258A EP 1414401 A1 EP1414401 A1 EP 1414401A1
Authority
EP
European Patent Office
Prior art keywords
skin
derivatives
prophylaxis
preparations
changes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02760258A
Other languages
German (de)
English (en)
Inventor
Helga Biergiesser
Thomas Blatt
Inge Kruse
Melanie Schmidt
Uwe SCHÖNROCK
Franz STÄB
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP1414401A1 publication Critical patent/EP1414401A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43—Guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/008—Preparations for oily hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to the use of combinations of creatinine and / or creatinine derivatives with creatine and / or its derivatives in cosmetic or dermatological preparations for the treatment and prophylaxis of the symptoms of UV and / or ozone-induced skin damage as well as inflammatory and degenerative skin conditions.
  • Cosmetic skin care is understood primarily to strengthen or restore the skin's natural function as a barrier against environmental influences (e.g., dirt, chemicals, microorganisms) and against the loss of endogenous substances (e.g., water, natural fats, electrolytes).
  • environmental influences e.g., dirt, chemicals, microorganisms
  • endogenous substances e.g., water, natural fats, electrolytes
  • the aim of skin care is also to compensate for the daily loss of fat and water loss of the skin. This is especially important when the natural regeneration capacity is insufficient.
  • skin care products to protect against environmental influences, especially from the sun and wind, and delay the aging of the skin.
  • the chronological skin aging is caused eg by endogenous, genetically determined factors.
  • the epidermis and der is due to aging, for example, the following structural damage and dysfunction, which may also fall under the term "senile xerosis”: a) dryness, roughness and development of dryness wrinkles; b) itching; and c) reduced rehydration through sebaceous glands (eg after washing).
  • Exogenous factors such as UV light and chemical noxae can be cumulatively effective and e.g. accelerate or supplement endogenous aging processes.
  • exogenous factors occur, e.g. on the following structural damage and dysfunction in the skin that go beyond the extent and quality of the damage caused by chronological aging:
  • the present invention relates in particular to products for the care of naturally aged skin, as well as for the treatment of the consequential damages of photoageing, in particular of the phenomena listed under a) to g).
  • Products for the care of aged skin are known per se. They contain e.g. Retinoids (vitamin A acid and / or derivatives thereof) or vitamin A and / or its derivatives. Their effect on the structural damage, however, is limited in scope. In addition, there are significant difficulties in product development in stabilizing the active ingredients sufficiently against oxidative degradation. In addition, the use of vitamin A acid-containing products often causes severe erythematous skin irritation. Retinoids can therefore only be used in low concentrations.
  • the present invention relates to cosmetic preparations with effective protection against harmful oxidation processes in the skin, but also to protect cosmetic preparations themselves or to protect the ingredients of cosmetic preparations from harmful oxidation processes.
  • UVC range rays with a wavelength less than 290 nm
  • UVB range rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema simple sunburn or even more or less severe burns.
  • UVA range it is important to have available filter substances, since its rays can cause reactions in photosensitive skin. It has been proven that UVA radiation leads to damage of the elastic and collagenous fibers of the connective tissue, which causes the skin to age prematurely, and that it is to be regarded as the cause of numerous phototoxic and photoallergic reactions. The damaging influence of UVB radiation can be amplified by UVA radiation.
  • UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products intervene in the skin metabolism.
  • such photochemical reaction products are free-radical compounds, for example hydroxy radicals.
  • Undefined radical photoproducts which are formed in the skin itself, can also show uncontrolled sequelae due to their high reactivity.
  • singlet oxygen a non-radical excited state of the oxygen molecule can occur on UV irradiation, as well as short-lived epoxides and many others. singlet For example, it is distinguished from the normally present triplet oxygen (radical ground state) by increased reactivity. However, there are also excited, reactive (radical) triplet states of the oxygen molecule.
  • UV radiation counts as ionizing radiation. There is thus the risk that ionic species may also be formed on exposure to UV radiation, which in turn may intervene oxidatively in the biochemical processes.
  • antioxidants and / or radical scavengers can be incorporated in the cosmetic or dermatological formulations.
  • vitamin E a substance with known antioxidant effect in sunscreen formulations, yet here again, the effect achieved far below the hoped for.
  • the object of the invention was therefore also to provide cosmetic, dermatological and pharmaceutical active ingredients and preparations as well as sunscreen formulations which are used for the prophylaxis and treatment of photosensitive skin, in particular photodermatoses, preferably PLD.
  • Mainly antioxidants are used as protective substances against spoilage of preparations containing them. Nevertheless, it is known that undesirable oxidation processes can also occur in human and animal skin. Such processes play an essential role in skin aging.
  • antioxidants and radical scavengers are known.
  • the object of the present invention was therefore to find ways that avoid the disadvantages of the prior art.
  • the effect of repairing the damage associated with endogenous, chronological and exogenous skin aging and the prophylaxis should be permanent, sustainable and without the risk of side effects.
  • Creatinine is included in meat extract and meatballs.
  • Creatine is formed in aqueous solution. In the organism it is formed by transamidation of L-arginine to glycine to guanidinoacetic acid and their subsequent methylation by means of S-adenosylmethionine (by guanidinoacetate methyltransferase). Creatine is thought to be an appetizing ingredient in beef and meat extract. Creatine supplementation increases physical performance.
  • Cosmetic or dermatological preparations according to the invention preferably comprise an active ingredient combination of 0.001-50% by weight, particularly preferably 0.01-15% by weight, very particularly preferably 0.1-8% by weight, of creatine and / or creatine derivatives with 0.001-50% by weight, particularly preferably 0.01-15% by weight, very particularly preferably 0.1-8% by weight of creatinine and / or creatinine derivatives, based on the total composition of the preparations. It is advantageous to choose the weight ratio of creatinine to creatine from the range of 50: 1 to 1:50, preferably from 10: 1 to 1:10, particularly preferably from 2: 1 to 1: 2.
  • Preferred derivative is the creatine phosphate, which has the following structure: and which is widespread in fresh muscle where it plays an important role as an energy-storing phosphate (Phosphagen).
  • Phosphagen an energy-storing phosphate
  • creatine phosphate with adenosine 5'-diphosphate under the influence of the enzyme creatine kinase, releases adenosine 5'-triphosphate (ATP) and creatine; in the resting muscle the reverse reaction takes place.
  • ATP adenosine 5'-triphosphate
  • JP2000 / 247866 describes skin cosmetics containing creatine and / or creatinine, which can be used as a cream or as a milky lotion, the preparations in question are said to have excellent skin-care properties.
  • this document could not pave the way for the present invention.
  • WO00 / 33787 describes the use of creatinine as an effective ingredient of deodorants. Even this document could not pave the way to the present invention.
  • EP-A 565 010 describes hair-growing and hair-dyeing preparations containing creatinine phosphate. Even this document could not pave the way to the present invention.
  • an effective way is surprisingly achieved Treatment, but also prophylaxis of deficient, sensitive or hypoactive skin conditions or deficient, sensitive or hypoactive states of skin attachment of premature aging of the skin (eg wrinkles, age spots, telangiectasias) and / or skin appendages, of environmental (smoking, smog , reactive oxygen species, free radicals) and in particular light-induced negative changes of the skin and the skin appendages, of light-induced skin damage from pigmentation disorders, itching, dry skin conditions and horny layer barrier disorders, hair loss and for improved hair growth of inflammatory skin conditions and atopic eczema, seborrheic dermatitis, polymorphic Light dermatosis, psoriasis, vitiligo possible.
  • combination of active ingredients also surprisingly serves to soothe sensitive or irritated skin to stimulate the collagen, hyaluronic acid, elastin synthesis to stimulate intracellular DNA synthesis, especially in deficient or hypoactive skin conditions.
  • to increase the cell renewal and regeneration of the skin to increase the skin's own protective and repair mechanisms (for example for dysfunctional enzymes, DNA, lipids, proteins) for the pre- and post-treatment in topical application of laser and Abschleifnessen z.
  • As the reduction of skin wrinkles and scars serve to counteract the resulting skin irritation and promote the regeneration processes in the injured skin.
  • the active ingredient combination or cosmetic or topical dermatological preparations used according to the invention with an effective content of active ingredient combination used according to the invention for cosmetic or dermatological treatment or prophylaxis. desired skin conditions to use.
  • preparations containing the active compound combinations according to the invention can be used with customary antioxidants.
  • the antioxidants are selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urotanic acid) and derivatives thereof, peptides such as D, L-camosine, D-carnosine, L- Camosin and its derivatives (eg anserine), carotenoids, carotenes (eg ⁇ -carotene, ⁇ -carotene, lycopene) and their derivatives, lipoic acid and its derivatives (eg dihydrolipoic acid), rothioglucose, propylthiouracil and other thiols (eg thioredoxin, glutathione , Cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl
  • ⁇ -hydroxyfatty acids eg citric acid, lactic acid, malic acid
  • humic acid eg citric acid, lactic acid, malic acid
  • bile acid bile extracts
  • bilirubin biliverdin
  • EDTA EDTA
  • EGTA EGTA and their derivatives
  • unsaturated fatty acids and their derivatives eg ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and its derivatives alaninediacetic acid, flavonoids, polyphenols, catechins, vitamin C and derivatives (eg ascorbyl palmitate, magnesium).
  • benzoic acid rutinic acid and its derivatives
  • the amount of antioxidants (one or more compounds) in the preparations is preferably from 0.001 to 30% by weight, particularly preferably from 0.05 to 20% by weight, in particular particular 1 - 10 wt .-%, based on the total weight of the preparation.
  • the prophylaxis or the cosmetic or dermatological treatment with the active ingredient combinations used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of the active ingredient combination used according to the invention is carried out in the usual way, in such a way that the active ingredient used according to the invention or the cosmetic or topical dermatological preparations having an effective content of active ingredient used according to the invention is applied to the affected skin areas.
  • the active ingredient combination used according to the invention can be incorporated into customary cosmetic and dermatological preparations which may be in various forms. So they can e.g. a solution, a water-in-oil (W / O) or oil-in-water (O / W) type emulsion, or a multiple emulsions, such as water-in-oil-in-water type (W / O / W) or oil-in-water-in-oil (O / W / O), a hydrodispersion or lipodispersion, a gel, a solid stick or even an aerosol.
  • W / O water-in-oil
  • O / W oil-in-water
  • O oil-in-water-in-oil
  • Emulsions according to the invention for the purposes of the present invention are advantageous and contain e.g. Fats, oils, waxes and / or other fatty substances, as well as water and one or more emulsifiers, as are commonly used for such a type of formulation.
  • Medicinal topical compositions according to the present invention usually contain one or more drugs in effective concentration.
  • drugs for the sake of simplicity, reference is made to the clear distinction between cosmetic and medical use and corresponding products to the statutory provisions of the Federal Republic of Germany (for example, Cosmetics Regulation, Food and Medicines Act).
  • cosmetic or topical dermatological compositions according to the present invention depending on their structure, for example, be used as skin protection cream, cleansing milk, sunscreen lotion, nutritional cream, day or night cream, etc. It may be possible and advantageous to use the compositions of the invention as a basis for pharmaceutical formulations use.
  • cosmetic and dermatological preparations which are in the form of a sunscreen agent are also advantageous.
  • these preferably additionally contain at least one UVA filter substance and / or at least one UVB filter substance and / or at least one inorganic pigment.
  • compositions according to the invention can advantageously contain substances which absorb UV radiation in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5% to 10% by weight, in particular 1% to 6 wt .-%, based on the total weight of the preparations.
  • the UVB filters may be oil-soluble or water-soluble.
  • oil-soluble substances are e.g. to call:
  • 4-aminobenzoic acid derivatives preferably (2- ethylhexyl) 4- (dimethylamino) benzoate, 4- (dimethylamino) benzoic acid amyl ester;
  • Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • esters of salicylic acid preferably 2-ethylhexyl salicylate, salicylic acid
  • Esters of benzalmalonic acid preferably di (2-ethylhexyl) 4-methoxybenzalmalonate
  • Sulfonic acid derivatives of benzophenones preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts;
  • Sulfonic acid derivatives of the 3-benzylidene camphor e.g. 4- (2-oxo-3-bomylidene-methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bomylidenemethyl) sulfonic acid and its salts.
  • UVB filters which can be used according to the invention should of course not be limiting.
  • the invention also relates to the combination of a UVA film according to the invention ters with a UVB filter or a cosmetic or dermatological preparation according to the invention which also contains a UVB filter.
  • UVA filters in formulations according to the invention which are customarily contained in cosmetic and / or dermatological preparations.
  • Such filter substances are preferably derivatives of dibenzoylmethane, in particular 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1, 3-dione and 1-phenyl-3- ( 4'-isopropylphenyl) propane-1,3-dione.
  • preparations containing these combinations are the subject of the invention.
  • the same quantities of UVA filter substances which have been mentioned for UVB filter substances can be used.
  • Cosmetic and / or dermatological preparations according to the present invention may also contain inorganic pigments which are commonly used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. Particular preference is given to pigments based on titanium dioxide. The amounts mentioned for the above combinations may be used.
  • the cosmetic and dermatological preparations according to the invention may contain cosmetic active substances, auxiliaries and / or additives such as are customarily used in such preparations, e.g. Antioxidants, preservatives, bactericides, perfumes, foaming inhibitors, colorants, pigments that have coloring properties, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other conventional ingredients of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic active substances e.g. Antioxidants, preservatives, bactericides, perfumes, foaming inhibitors, colorants, pigments that have coloring properties, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other conventional ingredients of a cosmetic or dermatological formulation such as alcohol
  • the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion
  • solvent Water or aqueous solutions of oils, such as triglycerides of capric or caprylic acid, but preferably castor oil;
  • Fats, waxes and other natural and synthetic fats preferably esters of fatty acids with lower C-number alcohols, e.g. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids of low C number or with fatty acids;
  • Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products ,
  • mixtures of the abovementioned solvents are used.
  • alcoholic solvents water can be another ingredient.
  • the oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions in the context of the present invention is advantageously selected from the group of esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of from 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of from 3 to 30 carbon atoms. atoms.
  • ester oils can then advantageously be selected from the group consisting of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2- Hexyldecyl stearate, 2-octyl dodecyl palmitate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate and also synthetic, semisynthetic and natural mixtures of such esters, eg Jojoba oil.
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and the fatty acid triglycerides, in particular the triglycerol esters of saturated and / or unsaturated saturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 8 to 24, in particular 12 to 18 carbon atoms.
  • the fatty acid triglycerides can be selected, for example, advantageously from the group of synthetic, semi-synthetic and natural oils, such as olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm oil and the like.
  • any mixtures of such oil and wax components are also advantageous to use in the context of the present invention. It may also be advantageous, if appropriate, to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • the oil phase is advantageously selected from the group consisting of 2-ethylhexyl isostearate, octyldodanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 12-15 -alkyl benzoate, caprylic-capric acid triglyceride, dicaprylyl ether.
  • Particularly advantageous are mixtures of C 12-15 -alkyl benzoate and 2-Ethylhexylisostea- rat, mixtures of C 12-15 -alkyl benzoate and Isotridecylisononanoat and mixtures of C 12 .
  • hydrocarbons paraffin oil, squalane and squalene are to be used advantageously in the context of the present invention.
  • the oil phase can also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or silicone oils.
  • cyclomethicone octamethylcyclotetrasiloxane
  • silicone oils are also advantageous for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • the aqueous phase of the preparations according to the invention advantageously contains alcohols, diols or polyols of low C number, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, di ethylene glycol monomethyl or monoethyl ether and analogous products, furthermore low C number alcohols, for example ethanol, isopropanol, 1,2-propanediol, glycerol, and in particular one or more thickening agents, which can be advantageously selected from the group silicon dioxide, aluminum silicates, Polysaccharides or their derivatives, for example
  • Gels used in the present invention usually contain low C number alcohols, e.g. Ethanol, isopropanol, 1, 2-propanediol, glycerol and water or an above-mentioned oil in the presence of a thickener which is preferably silica or an aluminosilicate in oily-alcoholic gels, in aqueous-alcoholic or alcoholic gels, preferably a polyacrylate.
  • a thickener which is preferably silica or an aluminosilicate in oily-alcoholic gels, in aqueous-alcoholic or alcoholic gels, preferably a polyacrylate.
  • Fixed pins contain e.g. natural or synthetic waxes, fatty alcohols or fatty acid esters.
  • Usual base materials which are suitable for use as cosmetic sticks in the context of the present invention are liquid oils (for example paraffin oils, castor oil, isopropyl myristate), semi-solid constituents (eg petrolatum, lanolin), solid constituents (eg beeswax, ceresin and microcrystalline Waxes or ozokerite) and high-melting waxes (eg carnauba wax, candelilla wax)
  • liquid oils for example paraffin oils, castor oil, isopropyl myristate
  • semi-solid constituents eg petrolatum, lanolin
  • solid constituents eg beeswax, ceresin and microcrystalline Waxes or ozokerite
  • high-melting waxes eg carnauba wax, candelilla wax
  • Suitable propellants for sprayable from aerosol containers cosmetic and / or dermatological preparations in the context of the present invention the usual known volatile, liquefied propellants, such as hydrocarbons (propane, butane, isobutane) are suitable, which can be used alone or in mixture with each other. Also, compressed air is advantageous to use.
  • hydrocarbons propane, butane, isobutane
  • compressed air is advantageous to use.
  • propellants which would be useful in the practice of the present invention in the form of aerosol preparations, but which should be avoided due to adverse environmental effects or other concomitant conditions, especially fluorocarbons and chlorofluorocarbons (US Pat. CFC).
  • Cosmetic preparations for the purposes of the present invention may also be present as gels which, in addition to an effective content of the active ingredient according to the invention and solvents used for this purpose, preferably water, are also organic thickeners, e.g. Gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose or inorganic thickeners, e.g. For example, aluminum silicates such as bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
  • the thickening agent is present in the gel e.g. in an amount of between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Préparations cosmétiques ou dermatologiques présentant une teneur d'une combinaison de principes actifs de créatinine et de créatine.
EP02760258A 2001-07-25 2002-07-22 Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques Ceased EP1414401A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10136076 2001-07-25
DE10136076A DE10136076A1 (de) 2001-07-25 2001-07-25 Verwendung von Kreatinin und/oder Kreatininderivaten in kosmetischen oder dermatologischen Zubereitungen
PCT/EP2002/008124 WO2003011241A1 (fr) 2001-07-25 2002-07-22 Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques

Publications (1)

Publication Number Publication Date
EP1414401A1 true EP1414401A1 (fr) 2004-05-06

Family

ID=7692944

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02760258A Ceased EP1414401A1 (fr) 2001-07-25 2002-07-22 Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques

Country Status (4)

Country Link
EP (1) EP1414401A1 (fr)
JP (1) JP2004538299A (fr)
DE (1) DE10136076A1 (fr)
WO (1) WO2003011241A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10301632A1 (de) * 2003-01-17 2004-07-29 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Kreatin, Kreatinin und/oder seinen Derivaten in Kombination mit Sojabohnenkeimextrakten
CA2678135C (fr) * 2003-02-28 2012-12-04 Elc Management Llc Procede permettant d'augmenter la pousse des cheveux au moyen d'un compose de creatine
DE10316666B4 (de) * 2003-04-10 2015-04-09 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin mit Kreatin und Coenzym Q10
DE10355717A1 (de) * 2003-11-26 2005-06-23 Beiersdorf Ag Kosmetische und dermatologische Emulsionen, enthaltend Kreatin und/oder Kreatinin mit gesteuerter Wasseraktivität
DE10355711A1 (de) * 2003-11-26 2005-06-16 Beiersdorf Ag Kosmetische und dermatologische Emulsionen, enthaltend Kreatin und/oder Kreatinin und Elektrolytkonzentrationen, einer Ionenstärke von mindestens 50 mmol/l
DE10355715A1 (de) * 2003-11-26 2005-06-16 Beiersdorf Ag Wirkstoffkombinationen Kreatin und/oder Kreatinderivaten und/oder Kreatinin und/oder Kreatininderivaten und einer wirksamen Menge an Retinoiden, insbesondere Retinol bzw. Retinylpalmitat und Zubereitungen, solche Wirkstoffkombinationen enthaltend
DE10355714A1 (de) 2003-11-26 2005-06-30 Beiersdorf Ag Wirkstoffkombination aus Kreatin und/oder Kreatinin, Phenoxyethanol und gewünschtenfalls Glycerin
DE10355716A1 (de) * 2003-11-26 2005-06-23 Beiersdorf Ag Kosmetische Zubereitungen mit einem Gehalt Kreatin und/oder Kreatinderivaten und/oder Kreatinin und/oderKreatininderivaten und organischen Verdickern
DE102004008440A1 (de) * 2004-02-19 2005-09-22 Stockhausen Gmbh Kosmetisches und/oder dermatologisches Mittel zur Steigerung des endogenen Lipidgehaltes der Haut
US20090105196A1 (en) * 2007-06-22 2009-04-23 Belinda Tsao Nivaggioli Use of creatine compounds to treat dermatitis
DE102007000799A1 (de) * 2007-10-01 2009-04-02 Beiersdorf Ag Verfahren zur Reduktion von Altershauterscheinungen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
US4590067A (en) * 1984-10-18 1986-05-20 Peritain, Ltd. Treatment for periodontal disease
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
JPH0797977B2 (ja) * 1987-04-21 1995-10-25 味の素株式会社 食品に煮干ダシの呈味を付与する方法
IT1258069B (it) * 1992-04-10 1996-02-20 Composizione per uso topico avente attivita' di stimolo per la ricrescita, di rinvigorimento, di prevenzione dell'ingrigimento e di ripigmentazione naturale dei capelli
GB9611356D0 (en) * 1996-05-31 1996-08-07 Howard Alan N Improvements in or relating to compositions containing Creatine, and other ergogenic compounds
DE19841385A1 (de) * 1998-09-10 2000-03-16 Sueddeutsche Kalkstickstoff Verwendung von Kreatin und/oder Kreatin-derivaten als Feuchthaltemittel in kosmetischen Zubereitungen
FR2786690A1 (fr) * 1998-12-08 2000-06-09 Oreal Composition cosmetique deodorante
JP3923226B2 (ja) * 1998-12-28 2007-05-30 ライオン株式会社 皮膚外用剤
WO2000059519A2 (fr) * 1999-03-31 2000-10-12 Kapitz Carl Heinz Substance active et combinaison de substances actives pour l'homme et les animaux
DE19963628A1 (de) * 1999-12-29 2001-07-12 Knapp Gerhard Kolostralmilch von Ziegen und Schafen und deren Verwendung in Kosmetika, Pharmazeutika sowie in Nahrungs- und Nahrungsergänzungsmiteln
ATE341948T1 (de) * 2001-03-02 2006-11-15 Howard Foundation Zusammensetzung enthaltend kreatin und kreatinin
DE10114561A1 (de) * 2001-03-24 2002-09-26 Wella Ag Verwendung von Mitteln enthaltend Kreatin, Kreatin und/oder deren Derivaten zur Verstärkung und Strukturverbesserung von keratinischen Fasern

Also Published As

Publication number Publication date
JP2004538299A (ja) 2004-12-24
WO2003011241A8 (fr) 2003-03-20
WO2003011241A1 (fr) 2003-02-13
DE10136076A1 (de) 2003-02-13

Similar Documents

Publication Publication Date Title
EP1642559B1 (fr) Utilisation de créatine et/ou de dérivés de créatine et de l'acide folique dans des préparations cosmétiques ou dermatologiques
EP0945126B1 (fr) Composition cosmétique ou dermatologique contenant de la carnitine et/ou un acylcarnitine et au moins un antioxydant
EP1594455B1 (fr) Preparations cosmetiques ou dermatologiques contenant de la creatine, de la creatinine et / ou leurs derives en combinaison avec des extraits de germe de graines de soja
DE19932197A1 (de) Topisch anzuwendendes Mittel mit schützender und regenerativer Wirkung
DE19806947A1 (de) Kosmetische oder dermatologische Wirkstoffkombinationen aus mindestens einer Substanz gewählt aus der Gruppe, bestehend aus Carnitin und den Acylcarnitinen, und mindestens einem Chinon und oder mindestens einem Hydrochinon sowie Zubereitungen mit einem Gehalt an solchen Wirkstoffkombinationen
EP1414402A1 (fr) Preparations cosmetiques ou dermatologiques a combinaison de creatinine et/ou de derives de creatinine avec la creatinine et ou ses derives
WO2002009652A2 (fr) Utilisation d'associations contenant des carnitines
EP3524236A1 (fr) Utilisation du licochalchone a ou d'un extrait du radix glycyrrhizae inflatae contenant du licochalchone a contre le vieillissement cutané
EP1414401A1 (fr) Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques
DE19806946A1 (de) Kosmetische oder dermatologische Wirkstoffkombinationen aus mindestens einer Substanz gewählt aus der Gruppe, bestehend aus Carnitin und den Acylcarnitinen, und mindestens einem Retinoid sowie Zubereitungen mit einem Gehalt an solchen Wirkstoffkombinationen
DE19806889A1 (de) Verwendung von Acyl-Carnitin
EP3658112B1 (fr) Associations de principes actifs comprenant du n-(4-amino-2-méthylchinolin-6-yl)-2-((4-éthylphénoxy)méthyle)benzamide et un ou plusieurs agents et/ou adjuvants de conservation cosmétiquement ou dermatologiquement acceptables
EP1000603B1 (fr) Utilisation d'esters tensioactifs d'acide citrique pour stabiliser de flavones, flavanones ou de flavonoides et mélanges synergiques, compositions cosmétiques et dermatologiques les contenant
EP3644953A1 (fr) Utilisation de n-(4-amino-2-méthylchinolin-6-yl)-2-((4-éthylphénoxy)méthyl)benzamide pour produire des préparations cosmétiques ou dermatologiques destinées au traitement thérapeutique et/ou prophylactique des symptômes du vieillissement cutané intrinsèque et/ou extrinsèque, ainsi que pour le traitement thérapeutique et prophylactique des effets nocifs des rayons ultraviolets sur la peau
DE102005035864A1 (de) Verwendung von Xanthohumol und/oder Isoxanthohumol zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe der Symptome der intrinsischen und/oder extrinsischen Hautalterung sowie zur Behandlung und Prophylaxe der schädlichen Auswirkungen ultravioletter Strahlung auf die Haut
DE10000840A1 (de) Verwendung eines oder mehrerer NO-Synthasehemmer
DE10316666B4 (de) Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin mit Kreatin und Coenzym Q10
DE10158076B4 (de) Kosmetische und/oder dermatologische Zubereitungen mit einem Gehalt an Aryl-Ureido-Verbindungen und ihre Verwendung
DE10048261A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Pyridoxamin zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE10127717A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Pyridoxin zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE102004039729A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an (-)2-Hydroxymethyl-2-Methyl-6-hydroxychromen bzw. einen Extrakt aus Pilzen der Art Daedalea quercina, (-)2-Hydroxymethyl-2-Methyl-6-hydrocychromen enthaltend
DE10127432A1 (de) Wirkstoffkombination zur Verhinderung unerwünschter Hautpigmentierung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040225

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: STAEB, FRANZ

Inventor name: SCHOENROCK, UWE

Inventor name: SCHMIDT, MELANIE

Inventor name: KRUSE, INGE

Inventor name: BLATT, THOMAS

Inventor name: BIERGIESSER, HELGA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20080711